## Guillermo E Umpierrez, Cde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3952826/publications.pdf

Version: 2024-02-01

344 papers

28,625 citations

7551 77 h-index 157 g-index

362 all docs 362 docs citations

times ranked

362

17414 citing authors

#	Article	IF	Citations
1	Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 978-982.	1.8	1,783
2	Hyperglycemic Crises in Adult Patients With Diabetes. Diabetes Care, 2009, 32, 1335-1343.	4.3	1,466
3	American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Diabetes Care, 2009, 32, 1119-1131.	4.3	1,115
4	Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Critical Care Medicine, 2012, 40, 3251-3276.	0.4	939
5	Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 16-38.	1.8	926
6	Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery). Diabetes Care, 2011, 34, 256-261.	4.3	594
7	Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. Diabetes Care, 2010, 33, 1783-1788.	4.3	573
8	Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial). Diabetes Care, 2007, 30, 2181-2186.	4.3	571
9	AACE/ADA Consensus Statement. Endocrine Practice, 2009, 15, 353-369.	1.1	472
10	Hyperglycemic Crises in Adult Patients With Diabetes: A consensus statement from the American Diabetes Association. Diabetes Care, 2006, 29, 2739-2748.	4.3	467
11	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015. Endocrine Practice, 2015, 21, 1-87.	1.1	443
12	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocrine Practice, 2020, 26, 107-139.	1.1	410
13	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	1.1	405
14	Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises. Diabetes, 2004, 53, 2079-2086.	0.3	400
15	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice, 2018, 24, 91-121.	1.1	388
16	American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary. Endocrine Practice, 2015, 21, 413-437.	1.1	359
17	Aace Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice, 2013, 19, 327-336.	1.1	318
18	Diabetic emergencies â€" ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology, 2016, 12, 222-232.	4.3	315

#	Article	IF	Citations
19	Perioperative Hyperglycemia and Risk of Adverse Events Among Patients With and Without Diabetes. Annals of Surgery, 2015, 261, 97-103.	2.1	303
20	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	15.2	299
21	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
22	Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care, 2014, 37, 2168-2176.	4.3	259
23	Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism: Clinical and Experimental, $2011$ , $60$ , $1-23$ .	1.5	253
24	Perioperative Hyperglycemia Management. Anesthesiology, 2017, 126, 547-560.	1.3	244
25	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocrine Practice, 2016, 22, 753-762.	1.1	242
26	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 2014, 37, 2149-2158.	4.3	236
27	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	13.9	228
28	Hyperglycemic Crises in Diabetes. Diabetes Care, 2004, 27, S94-S102.	4.3	226
29	Narrative Review: Ketosis-Prone Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2006, 144, 350.	2.0	218
30	Hyperglycemic Crises in Urban Blacks. Archives of Internal Medicine, 1997, 157, 669.	4.3	213
31	Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial. Diabetes Care, 2015, 38, 1665-1672.	4.3	210
32	Diabetic Ketoacidosis in Obese African-Americans. Diabetes, 1995, 44, 790-795.	0.3	207
33	Hyperosmolar Hyperglycemic State: A Historic Review of the Clinical Presentation, Diagnosis, and Treatment. Diabetes Care, 2014, 37, 3124-3131.	4.3	206
34	Treatment of Diabetic Ketoacidosis With Subcutaneous Insulin Aspart. Diabetes Care, 2004, 27, 1873-1878.	4.3	204
35	Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. American Journal of Medicine, 2004, 117, 291-296.	0.6	194
36	Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes. Diabetes Care, 2011, 34, 2508-2514.	4.3	190

#	Article	IF	CITATIONS
37	AACE/ACE Comprehensive Diabetes Management Algorithm 2015. Endocrine Practice, 2015, 21, 438-447.	1.1	189
38	Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2169-2174.	4.3	183
39	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. JAMA - Journal of the American Medical Association, 2021, 325, 2262.	3.8	182
40	Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care, 2018, 41, 1579-1589.	4.3	175
41	Thirty Years of Personal Experience in Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1541-1552.	1.8	170
42	Diabetic ketoacidosis. Nature Reviews Disease Primers, 2020, 6, 40.	18.1	165
43	Thyroid Dysfunction in Patients With Type 1 Diabetes: A longitudinal study. Diabetes Care, 2003, 26, 1181-1185.	4.3	160
44	Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients. Diabetes Care, 2013, 36, 4091-4097.	4.3	160
45	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, 2016, 39, 222-230.	4.3	158
46	Recurrent Diabetic Ketoacidosis in Inner-City Minority Patients. Diabetes Care, 2011, 34, 1891-1896.	4.3	157
47	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	6.3	155
48	Diabetic Ketoacidosis. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 95-108.	1.8	154
49	Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 564-569.	1.8	150
50	Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 3430-3435.	4.3	145
51	Sliding Scale Insulin Use: Myth or Insanity?. American Journal of Medicine, 2007, 120, 563-567.	0.6	137
52	Management of Hyperglycemic Crises. Medical Clinics of North America, 2017, 101, 587-606.	1.1	135
53	Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action. Diabetes Care, 2013, 36, 1807-1814.	4.3	134
54	Diabetic muscle infarction. American Journal of Medicine, 1996, 101, 245-250.	0.6	132

#	Article	IF	CITATIONS
55	Abdominal pain in patients with hyperglycemic crises. Journal of Critical Care, 2002, 17, 63-67.	1.0	132
56	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice, 2013, 19, 1-48.	1.1	132
57	Hyperglycemia During Total Parenteral Nutrition. Diabetes Care, 2010, 33, 739-741.	4.3	130
58	Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 125-133.	<b>5.</b> 5	128
59	Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes and Endocrinology,the, 2021, 9, 174-188.	5.5	127
60	Health Literacy, Self-efficacy, Food Label Use, and Diet in Young Adults. American Journal of Health Behavior, 2014, 38, 331-339.	0.6	126
61	Sulfonylureas: A New Look at Old Therapy. Current Diabetes Reports, 2014, 14, 473.	1.7	121
62	Management of Hyperglycemia During Enteral and Parenteral Nutrition Therapy. Current Diabetes Reports, 2013, 13, 155-162.	1.7	119
63	Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis: A randomized controlled trial. Diabetes Care, 2009, 32, 1164-1169.	4.3	110
64	Admission Hyperglycemia and Other Risk Factors as Predictors of Hospital Mortality in a Medical ICU Population. Chest, 2005, 128, 3109-3116.	0.4	105
65	Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension. Diabetes Care, 2007, 30, 1699-1703.	4.3	104
66	Management of Inpatient Hyperglycemia and Diabetes in Older Adults. Diabetes Care, 2017, 40, 509-517.	4.3	104
67	Perioperative Glucose Control in the Diabetic or Nondiabetic Patient. Southern Medical Journal, 2006, 99, 580-589.	0.3	103
68	Differences in metabolic and hormonal milieu in diabetic- and alcohol-induced ketoacidosis. Journal of Critical Care, 2000, 15, 52-59.	1.0	102
69	Glycemic control in non-diabetic critically ill patients. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 813-824.	2.2	102
70	Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Research and Care, 2015, 3, e000108.	1.2	101
71	Consensus Statement on Inpatient Use of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2017, 11, 1036-1044.	1.3	99
72	Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes. American Journal of the Medical Sciences, 2018, 356, 518-527.	0.4	95

#	Article	IF	CITATIONS
73	Hospital Discharge Algorithm Based on Admission HbA1c for the Management of Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 2934-2939.	4.3	94
74	Diabetes and fractures: an overshadowed association. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 435-445.	1,2	91
75	Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2101-2128.	1.8	90
76	Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 2211-2216.	4.3	87
77	Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic. Journal of Diabetes Science and Technology, 2020, 14, 822-832.	1.3	86
78	Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity. Metabolism: Clinical and Experimental, 2020, 108, 154224.	1.5	83
79	Insulin Therapy for the Management of Hyperglycemia in Hospitalized Patients. Endocrinology and Metabolism Clinics of North America, 2012, 41, 175-201.	1.2	82
80	Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen. Diabetes Care, 2020, 43, 2730-2735.	4.3	82
81	Diabetes Complications in Racial and Ethnic Minority Populations in the USA. Current Diabetes Reports, 2021, 21, 2.	1.7	82
82	Hyperglycemic Crises in Patients With Diabetes Mellitus. Diabetes Care, 2003, 26, S109-S117.	4.3	80
83	Reducing Inpatient Hypoglycemia in the General Wards Using Real-time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial. Diabetes Care, 2020, 43, 2736-2743.	4.3	79
84	Glycemic chaos (not glycemic control) still the rule for inpatient care. Journal of Hospital Medicine, 2006, 1, 141-144.	0.7	78
85	Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic. Diabetes Care, 2021, 44, 847-849.	4.3	78
86	Predictors of intensive care unit and hospital length of stay in diabetic ketoacidosis. Journal of Critical Care, 2002, 17, 207-211.	1.0	77
87	Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. Journal of Diabetes Science and Technology, 2020, 14, 1035-1064.	1.3	77
88	Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocrine Reviews, 2020, 41, 756-774.	8.9	77
89	The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes, Obesity and Metabolism, 2011, 13, 418-425.	2.2	75
90	Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Current Medical Research and Opinion, 2006, 22, 751-759.	0.9	74

#	Article	IF	CITATIONS
91	A double-blind, randomized clinical trial comparing soybean oil–based versus olive oil–based lipid emulsions in adult medical–surgical intensive care unit patients requiring parenteral nutrition*. Critical Care Medicine, 2012, 40, 1792-1798.	0.4	74
92	Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Nonketotic Syndrome. American Journal of the Medical Sciences, 1996, 311, 225-233.	0.4	74
93	Posttraumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population. General Hospital Psychiatry, 2011, 33, 135-142.	1.2	73
94	Update on Diabetes in the Elderly and in Nursing Home Residents. Journal of the American Medical Directors Association, 2011, 12, 627-632.e2.	1.2	69
95	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	1.3	69
96	Congestive Heart Failure Due to Reversible Cardiomyopathy in Patients With Hyperthyroidism. American Journal of the Medical Sciences, 1995, 310, 99-102.	0.4	68
97	Evidence for strict inpatient blood glucose control: time to revise glycemic goals in hospitalized patients. Metabolism: Clinical and Experimental, 2008, 57, 116-120.	1.5	67
98	A comparison study of continuous insulin infusion protocols in the medical intensive care unit: Computerâ€guided vs. standard columnâ€based algorithms. Journal of Hospital Medicine, 2010, 5, 432-437.	0.7	67
99	Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non–Critically Ill Hospitalized Patients With Diabetes. Diabetes Care, 2021, 44, 1641-1646.	4.3	66
100	Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Research and Care, 2020, 8, e001248.	1.2	65
101	Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis. Diabetes Care, 2021, 44, 578-585.	4.3	65
102	Impact of Diabetes Mellitus on Perioperative Outcomes after Resection for Pancreatic Adenocarcinoma. Journal of the American College of Surgeons, 2010, 210, 463-473.	0.2	63
103	Management of hyperglycemia in hospitalized patients. Annals of the New York Academy of Sciences, 2010, 1212, 1-11.	1.8	63
104	Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study. Diabetes Care, 2020, 43, 349-357.	4.3	62
105	Risk Factors for Inpatient Hypoglycemia during Subcutaneous Insulin Therapy in Non-Critically III Patients with Type 2 Diabetes. Journal of Diabetes Science and Technology, 2012, 6, 1022-1029.	1.3	61
106	Continuous Glucose Monitoring Versus Capillary Point-of-Care Testing for Inpatient Glycemic Control in Type 2 Diabetes Patients Hospitalized in the General Ward and Treated With a Basal Bolus Insulin Regimen. Journal of Diabetes Science and Technology, 2016, 10, 325-329.	1.3	61
107	National Trends in Incidence, Mortality, and Clinical Outcomes of Patients Hospitalized for Thyrotoxicosis With and Without Thyroid Storm in the United States, 2004–2013. Thyroid, 2019, 29, 36-43.	2.4	61
108	Intravenous Intralipid-Induced Blood Pressure Elevation and Endothelial Dysfunction in Obese African-Americans with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 609-614.	1.8	60

#	Article	IF	Citations
109	A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 450-456.	4.3	60
110	Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus. Diabetes Management, 2011, 1, 589-600.	0.5	59
111	Comparative Analysis of the Efficacy of Continuous Glucose Monitoring and Self-Monitoring of Blood Glucose in Type 1 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2012, 6, 1094-1102.	1.3	59
112	Diabetes Mellitus in the Hispanic/Latino Population: An Increasing Health Care Challenge in the United States. American Journal of the Medical Sciences, 2007, 334, 274-282.	0.4	58
113	Glycemic variability and cardiovascular disease in patients with type 2 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002032.	1.2	55
114	Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2015, 29, 433-437.	1.2	54
115	Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochemical and Biophysical Research Communications, 2004, 315, 404-407.	1.0	53
116	Glycaemic efficacy and safety of linagliptin compared to a basalâ€bolus insulin regimen in patients with type 2 diabetes undergoing nonâ€cardiac surgery: A multicentre randomized clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 837-843.	2.2	53
117	Therapy Insight: metabolic and endocrine disorders in sickle cell disease. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 102-109.	2.9	52
118	Diabetic Ketoacidosis: A Common Debut of Diabetes Among African Americans With Type 2 Diabetes. Endocrine Practice, 2017, 23, 971-978.	1.1	52
119	Glucose Control, Diabetes Status, and Mortality in Critically Ill Patients. Mayo Clinic Proceedings, 2017, 92, 1019-1029.	1.4	51
120	Substitution of Standard Soybean Oil with Olive Oil-Based Lipid Emulsion in Parenteral Nutrition: Comparison of Vascular, Metabolic, and Inflammatory Effects. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3207-3216.	1.8	50
121	The Effect of Continuous Glucose Monitoring in Preventing Inpatient Hypoglycemia in General Wards: The Glucose Telemetry System. Journal of Diabetes Science and Technology, 2018, 12, 20-25.	1.3	50
122	Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept. Diabetes Care, 2021, 44, 1055-1058.	4.3	50
123	Management of Hyperglycemia in Diabetic Patients with Hematologic Malignancies During Dexamethasone Therapy. Endocrine Practice, 2013, 19, 231-235.	1.1	48
124	Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?. Diabetes Care, 2013, 36, 2112-2117.	4.3	47
125	Adrenal Myelolipoma Associated With Endocrine Dysfunction: Review of the Literature. American Journal of the Medical Sciences, 1997, 314, 338-341.	0.4	46
126	The impact of hyperglycemia and obesity on hospitalization costs and clinical outcome in general surgery patients. Journal of Diabetes and Its Complications, 2015, 29, 1177-1182.	1.2	45

#	Article	IF	CITATIONS
127	Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19. JAMA Network Open, 2021, 4, e211091.	2.8	45
128	Pregnancy Complicated by Diabetic Ketoacidosis: Maternal and fetal outcomes. Diabetes Care, 2003, 26, 958-959.	4.3	44
129	Prevalence, Quality of Care, and Complications in Long Term Care Residents With Diabetes: A Multicenter Observational Study. Journal of the American Medical Directors Association, 2013, 14, 842-846.	1.2	44
130	Glucose Variability is an Independent Predictor of Mortality in Hospitalized Patients Treated with Total Parenteral Nutrition. Endocrine Practice, 2014, 20, 41-45.	1.1	44
131	Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios. Diabetes Therapy, 2018, 9, 1775-1789.	1.2	43
132	Debate on Insulin vs Non-insulin Use in the Hospital Settingâ€"Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?. Current Diabetes Reports, 2019, 19, 65.	1.7	43
133	Basal Versus Sliding-Scale Regular Insulin in Hospitalized Patients With Hyperglycemia During Enteral Nutrition Therapy. Diabetes Care, 2009, 32, 751-753.	4.3	42
134	Effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E953-E958.	1.8	42
135	Basal-Bolus Regimen With Insulin Analogues Versus Human Insulin in Medical Patients with type 2 Diabetes: A Randomized Controlled Trial in Latin America. Endocrine Practice, 2015, 21, 807-813.	1.1	41
136	Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients. Endocrinology and Metabolism Clinics of North America, 2018, 47, 203-222.	1.2	41
137	Metformin-Associated Lactic Acidosis. American Journal of the Medical Sciences, 2015, 349, 263-267.	0.4	40
138	Predictive Value of Admission Hemoglobin A1c on Inpatient Glycemic Control and Response to Insulin Therapy in Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, e202-e203.	4.3	40
139	Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. Journal of Clinical Anesthesia, 2017, 36, 184-188.	0.7	40
140	Safety and efficacy of continuous insulin infusion in noncritical care settings. Journal of Hospital Medicine, 2010, 5, 212-217.	0.7	39
141	Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placeboâ€controlled 54â€week trial in patients with type 2 diabetes (一项为期54å"çš"å⁻¹æŒDiabetes, 2013, 5, 68-79.	Ε <b>φ.:8</b> ½;ç"	¨ <b>ℬ</b> Œҫ"²åŒċ
142	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39
143	Contributions of Basal and Prandial Hyperglycemia to Total Hyperglycemia in Older and Younger Adults with Type 2 Diabetes Mellitus. Journal of the American Geriatrics Society, 2013, 61, 535-541.	1.3	38
144	Continuous Glucose Monitoring in Insulin-Treated Patients in Non-ICU Settings. Journal of Diabetes Science and Technology, 2014, 8, 930-936.	1.3	38

#	Article	IF	Citations
145	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Therapy, 2015, 6, 127-142.	1.2	37
146	Stress hyperglycemia in general surgery: Why should we care?. Journal of Diabetes and Its Complications, 2018, 32, 305-309.	1.2	37
147	American Association of Clinical Endocrinologists And American College of Endocrinology 2018 Position Statement On Integration of Insulin Pumps And Continuous Glucose Monitoring In Patients With Diabetes Mellitus. Endocrine Practice, 2018, 24, 302-308.	1.1	37
148	Increasing Hospitalizations for DKA: A Need for Prevention Programs. Diabetes Care, 2018, 41, 1839-1841.	4.3	37
149	Inpatient hyperglycemia management: A practical review for primary medical and surgical teams. Cleveland Clinic Journal of Medicine, 2016, 83, S34-S43.	0.6	37
150	Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia. Journal of Diabetes and Its Complications, 2012, 26, 257-258.	1.2	36
151	Medical Nutrition Therapy in Hospitalized Patients with Diabetes. Current Diabetes Reports, 2012, 12, 93-100.	1.7	36
152	Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. Diabetes Therapy, 2017, 8, 953-962.	1.2	36
153	Diabetes Technology in the Inpatient Setting for Management of Hyperglycemia. Endocrinology and Metabolism Clinics of North America, 2020, 49, 79-93.	1.2	36
154	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY—CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN–2015–EXECUTIVE SUMMARY. Endocrine Practice, 2015, 21, 413-37.	1.1	36
155	Low Testosterone Concentration and Atherosclerotic Disease Markers in Male Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4698-4703.	1.8	35
156	Comparison of Computer-Guided Versus Standard Insulin Infusion Regimens in Patients With Diabetic Ketoacidosis. Journal of Diabetes Science and Technology, 2018, 12, 39-46.	1.3	34
157	Global status of diabetes prevention and prospects for action: A consensus statement. Diabetes/Metabolism Research and Reviews, 2018, 34, e3021.	1.7	34
158	American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action. Endocrine Practice, 2014, 20, 956-976.	1.1	33
159	A randomized controlled trial comparing treatment with oral agents and basal insulin in elderly patients with type 2 diabetes in long-term care facilities. BMJ Open Diabetes Research and Care, 2015, 3, e000104.	1.2	33
160	Guidelines for management of diabetic ketoacidosis: time to revise?. Lancet Diabetes and Endocrinology,the, 2017, 5, 321-323.	5.5	33
161	The Use of Alkali Therapy in Severe Diabetic Ketoacidosis. Diabetes Care, 2002, 25, 2113-2114.	4.3	32
162	Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Diabetes Spectrum, 2014, 27, 180-188.	0.4	32

#	Article	IF	Citations
163	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrology Dialysis Transplantation, 2022, 37, 1261-1269.	0.4	32
164	Individualizing Inpatient Diabetes Management During the Coronavirus Disease 2019 Pandemic. Journal of Diabetes Science and Technology, 2020, 14, 705-707.	1.3	31
165	Continuous Glucose Monitoring in the Operating Room and Cardiac Intensive Care Unit. Diabetes Care, 2021, 44, e50-e52.	4.3	31
166	A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial. Journal of the American Medical Directors Association, 2018, 19, 399-404.e3.	1,2	30
167	The differential effects of PTSD, MDD, and dissociation on CRP in trauma-exposed women. Comprehensive Psychiatry, 2019, 93, 33-40.	1.5	30
168	Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment. Diabetes, Obesity and Metabolism, 2021, 23, 2632-2642.	2.2	30
169	Collagen Production in Fasted and Food-Restricted Rats: Response to Duration and Severity of Food Deprivation. Journal of Nutrition, 1991, 121, 518-524.	1.3	29
170	Lack of Lipotoxicity Effect on Â-Cell Dysfunction in Ketosis-Prone Type 2 Diabetes. Diabetes Care, 2010, 33, 626-631.	4.3	29
171	Effects of Intravenous Glucose Load on Insulin Secretion in Patients With Ketosis-Prone Diabetes During Near-Normoglycemia Remission. Diabetes Care, 2010, 33, 854-860.	4.3	29
172	The Emory University Perioperative Algorithm for the Management of Hyperglycemia and Diabetes in Non-cardiac Surgery Patients. Current Diabetes Reports, 2016, 16, 34.	1.7	29
173	Stress Hyperglycemia in Patients with Tuberculosis Disease: Epidemiology and Clinical Implications. Current Diabetes Reports, 2018, 18, 71.	1.7	29
174	ICU care for patients with diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 75-81.	0.6	28
175	Randomized Controlled Trial of Insulin Supplementation for Correction of Bedtime Hyperglycemia in Hospitalized Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 568-574.	4.3	27
176	Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving onceâ€weekly dulaglutide treatment. Diabetes, Obesity and Metabolism, 2016, 18, 615-622.	2.2	27
177	Vascular effects of intravenous intralipid and dextrose infusions in obese subjects. Metabolism: Clinical and Experimental, 2012, 61, 1370-1376.	1.5	26
178	What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Diabetes Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2021, 23, 652-660.	2.4	26
179	Management of Breast Abscesses in Nonlactating Women. American Surgeon, 2010, 76, 292-295.	0.4	25
180	Management of Type 1 Diabetes in the Hospital Setting. Current Diabetes Reports, 2017, 17, 98.	1.7	25

#	Article	IF	Citations
181	Diabetic ketoacidosis in type 2 diabetes mellitusâ€"pathophysiology and clinical presentation. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 730-731.	2.9	24
182	Lifestyle habits and obesity progression in overweight and obese American young adults: Lessons for promoting cardiometabolic health. Australian Journal of Cancer Nursing, 2015, 17, 467-475.	0.8	24
183	Emotion Dysregulation and Inflammation in African-American Women with Type 2 Diabetes. Neural Plasticity, 2016, 2016, 1-10.	1.0	24
184	Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy. Journal of Diabetes and Its Complications, 2017, 31, 742-747.	1.2	24
185	A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial. Diabetes Care, 2020, 43, 1242-1248.	4.3	24
186	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care, 2021, 44, 2729-2737.	4.3	24
187	Ketosis-Prone Type 2 Diabetes: Effect of Hyperglycemia on $\hat{I}^2$ -Cell Function and Skeletal Muscle Insulin Signaling. Endocrine Practice, 2007, 13, 283-290.	1.1	23
188	Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes. Postgraduate Medicine, 2014, 126, 60-71.	0.9	23
189	Accuracy and Precision of Continuous Glucose Monitoring in Hospitalized Patients Undergoing Radiology Procedures. Journal of Diabetes Science and Technology, 2020, 14, 1135-1136.	1.3	23
190	A Feasibility Study to Develop a Diabetes Prevention Program for Young Adults With Prediabetes by Using Digital Platforms and a Handheld Device. The Diabetes Educator, 2014, 40, 626-637.	2.6	22
191	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. Endocrine Practice, 2015, 21, 1403-1414.	1.1	22
192	Clinical characteristics and outcomes of symptomatic and asymptomatic hypoglycemia in hospitalized patients with diabetes. BMJ Open Diabetes Research and Care, 2018, 6, e000607.	1.2	22
193	Association of Glucose Concentrations at Hospital Discharge With Readmissions and Mortality: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3679-3691.	1.8	22
194	Sociodemographic, Clinical, and Treatment-Related Factors Associated With Hyperglycemic Crises Among Adults With Type 1 or Type 2 Diabetes in the US From 2014 to 2020. JAMA Network Open, 2021, 4, e2123471.	2.8	22
195	Use Of Incretin-Based Therapy in Hospitalized Patients with Hyperglycemia. Endocrine Practice, 2014, 20, 933-944.	1.1	21
196	Associations of childhood trauma with food addiction and insulin resistance in African-American women with diabetes mellitus. Appetite, 2019, 141, 104317.	1.8	21
197	Changes in Serum Leptin in Lean and Obese Subjects with Acute Hyperglycemic Crises. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2593-2596.	1.8	20
198	Daily Inpatient Glycemic Survey (DINGS): A Process to Remotely Identify and Assist in the Management of Hospitalized Patients with Diabetes and Hyperglycemia. Endocrine Practice, 2015, 21, 927-935.	1.1	20

#	Article	IF	CITATIONS
199	SGLT2 inhibitors and diabetic ketoacidosis — a growing concern. Nature Reviews Endocrinology, 2017, 13, 441-442.	4.3	20
200	When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control. Diabetes, Obesity and Metabolism, 2019, 21, 1305-1310.	2.2	20
201	Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises. Diabetes Care, 2016, 39, 1948-1955.	4.3	19
202	Transcultural Diabetes Care in The United States $\hat{a} \in \text{``A Position Statement by the American Association of Clinical Endocrinologists. Endocrine Practice, 2019, 25, 729-765.}$	1.1	19
203	Continuous Glucose Monitoring in General Wards for Prevention of Hypoglycemia: Results From the Glucose Telemetry System Pilot Study. Journal of Diabetes Science and Technology, 2020, 14, 783-790.	1.3	19
204	Breast Abscesses in Nonlactating Women With Diabetes: Clinical Features and Outcome. American Journal of the Medical Sciences, 2009, 338, 123-126.	0.4	18
205	Management of Intractable Hypoglycemia With Yttirum-90 Radioembolization in a Patient With Malignant Insulinoma. American Journal of the Medical Sciences, 2010, 340, 414-417.	0.4	18
206	Point-of-care capillary HbA1c measurement in the emergency department: a useful tool to detect unrecognized and uncontrolled diabetes. International Journal of Emergency Medicine, 2016, 9, 7.	0.6	18
207	Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: <scp>R</scp> eview of current strategies. Journal of Diabetes, 2018, 10, 94-111.	0.8	18
208	Emerging trends and the clinical impact of food insecurity in patients with diabetes. Journal of Diabetes, 2020, 12, 187-196.	0.8	18
209	Continuous Ketone Monitoring Consensus Report 2021. Journal of Diabetes Science and Technology, 2022, 16, 689-715.	1.3	18
210	How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes? Diabetes Research and Clinical Practice, 2015, 108, 179-186.	1.1	17
211	Comparison of Efficacy and Safety of Glargine and Detemir Insulin in the Management of Inpatient Hyperglycemia and Diabetes. Endocrine Practice, 2017, 23, 1059-1066.	1.1	17
212	Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 2465-2473.	2.2	17
213	Special considerations on the management of Latino patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2011, 27, 969-979.	0.9	16
214	Inpatient dysglycemia and clinical outcomes: Association or causation?. Journal of Diabetes and Its Complications, 2014, 28, 427-429.	1.2	16
215	Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?. Diabetes Research and Clinical Practice, 2018, 142, 19-25.	1.1	16
216	Insulin glargine/lixisenatide fixedâ€ratio combination improves glycaemic variability and control without increasing hypoglycaemia. Diabetes, Obesity and Metabolism, 2019, 21, 726-731.	2.2	16

#	Article	lF	CITATIONS
217	Barriers to diabetic foot care in a disadvantaged population: A qualitative assessment. Journal of Diabetes and Its Complications, 2020, 34, 107688.	1.2	16
218	Safety And Efficacy Of Dpp-4 Inhibitors For The Management Of Hospitalized General Medicine And Surgery Patients with Type 2 Diabetes. Endocrine Practice, 2020, 26, 722-728.	1.1	16
219	Nebivolol in Highâ€Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function. Journal of Clinical Hypertension, 2009, 11, 720-725.	1.0	15
220	Report on Racial Disparities in Hospitalized Patients with Hyperglycemia and Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1144-1150.	1.8	15
221	Impact of obesity on hospital complications and mortality in hospitalized patients with hyperglycemia and diabetes. BMJ Open Diabetes Research and Care, 2016, 4, e000200.	1.2	15
222	Clinical characteristics and outcomes of patients with end-stage renal disease hospitalized with diabetes ketoacidosis. BMJ Open Diabetes Research and Care, 2020, 8, e000763.	1.2	15
223	Inpatient Glycemic Control With Sliding Scale Insulin in Noncritical Patients With Type 2 Diabetes: Who Can Slide?. Journal of Hospital Medicine, 2021, 16, 462-468.	0.7	15
224	Diabetic ketoacidosis risk during the COVID-19 pandemic. Lancet Diabetes and Endocrinology,the, 2021, 9, 643-644.	5.5	15
225	Relative Hypoglycemia and Lower Hemoglobin A1c-Adjusted Time in Band Are Strongly Associated With Increased Mortality in Critically Ill Patients. Critical Care Medicine, 2022, 50, e664-e673.	0.4	15
226	Euthyroid sick syndrome. Southern Medical Journal, 2002, 95, 506-13.	0.3	15
227	Characteristics of American Young Adults With Increased Risk for Type 2 Diabetes. The Diabetes Educator, 2013, 39, 454-463.	2.6	14
228	The Efficacy and Safety of Co-Administration of Sitagliptin With Metformin in Patients With Type 2 Diabetes at Hospital Discharge. Endocrine Practice, 2018, 24, 556-564.	1.1	14
229	Percutaneous Bone Biopsy for Diabetic Foot Osteomyelitis: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa393.	0.4	14
230	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINEâ€HF</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1426-1430.	2.2	14
231	Do obese children with diabetic ketoacidosis have type $1$ or type $2$ diabetes?. Primary Care Diabetes, $2012, 6, 61-65$ .	0.9	13
232	Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2015, 9, 1227-1235.	1.3	13
233	Social vulnerability and hypoglycemia among patients with diabetes. Endocrinologia, Diabetes Y NutriciÓn, 2017, 64, 92-99.	0.1	13
234	Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study. Journal of Diabetes and Its Complications, 2018, 32, 1091-1096.	1.2	13

#	Article	IF	CITATIONS
235	Prediabetes and working memory in older adults. Brain and Neuroscience Advances, 2020, 4, 239821282096172.	1.8	13
236	Clinical decision support to improve management of diabetes and dysglycemia in the hospital: a path to optimizing practice and outcomes. BMJ Open Diabetes Research and Care, 2021, 9, e001557.	1.2	13
237	Glycemic control metrics using flash glucose monitoring and hospital complications in patients with COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 499-503.	1.8	13
238	Management of breast abscesses in nonlactating women. American Surgeon, 2010, 76, 292-5.	0.4	13
239	Insulin Resistance and Pubertal Changes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2472-2473.	1.8	12
240	Inflammation and Oxidative Stress in Cardiac Surgery Patients Treated to Intensive vs. Conservative Glucose Targets. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-3197.	1.8	12
241	A Milestone in Point of Care Capillary Blood Glucose Monitoring of Critically III Hospitalized Patients. Journal of Diabetes Science and Technology, 2018, 12, 1095-1100.	1.3	12
242	Efficacy of a Smart Insulin Pen Cap for the Management of Patients with Uncontrolled Type 2 Diabetes: A Randomized Cross-Over Trial. Journal of Diabetes Science and Technology, 2023, 17, 201-207.	1.3	12
243	Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 42-49.	2.2	12
244	Metformin/rosiglitazone combination pill (Avandamet $\hat{A}^{@}$ ) for the treatment of patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2007, 8, 1353-1364.	0.9	11
245	Introduction: Overview of efforts and lessons learned. Journal of Hospital Medicine, 2008, 3, 1-5.	0.7	11
246	Lixisenatide reduces glycaemic variability in insulinâ€treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1317-1321.	2.2	11
247	Hypoglycemic and Hyperglycemic Crises Among U.S. Adults With Diabetes and End-stage Kidney Disease: Population-Based Study, 2013–2017. Diabetes Care, 2022, 45, 100-107.	4.3	11
248	Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices. Current Diabetes Reports, 2022, 22, 237-246.	1.7	11
249	Hyperglycemia is Associated with Increased Hospital Complications and Mortality During Parenteral Nutrition. Hospital Practice (1995), 2011, 39, 81-88.	0.5	10
250	Management of the Hospitalized Patient With Type I Diabetes Mellitus. Hospital Practice (1995), 2013, 41, 89-100.	0.5	10
251	Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. Postgraduate Medicine, 2015, 127, 251-257.	0.9	10
252	Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2020, 14, 233-239.	1.3	10

#	Article	IF	CITATIONS
253	Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge. Diabetes, Obesity and Metabolism, 2021, 23, 1351-1360.	2.2	10
254	Emotion dysregulation and dissociation contribute to decreased heart rate variability to an acute psychosocial stressor in trauma-exposed Black women. Journal of Psychiatric Research, 2021, 142, 125-131.	1.5	10
255	Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice. Endocrine Practice, 2013, 19, 718-728.	1.1	9
256	Impact of periodontal disease on outcomes in diabetes. Contemporary Clinical Trials, 2015, 41, 93-99.	0.8	9
257	Perspectives on Learning and Clinical Practice Improvement for Diabetes in the Hospital: A Review of Educational Interventions for Providers. Endocrine Practice, 2017, 23, 614-626.	1.1	9
258	Acute and Chronic Glucose Control in Critically Ill Patients With Diabetes: The Impact of Prior Insulin Treatment. Journal of Diabetes Science and Technology, 2022, 16, 1483-1495.	1.3	9
259	How to manage type 2 diabetes in medical and surgical patients in the hospital. Cleveland Clinic Journal of Medicine, 2011, 78, 379-384.	0.6	9
260	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diabetes and Vascular Disease Research, 2008, 5, 276-284.	0.9	8
261	Inpatient Use of Computer-Guided Insulin Devices Moving into the Non–Intensive Care Unit Setting. Diabetes Technology and Therapeutics, 2015, 17, 673-675.	2.4	8
262	How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes? Diabetes Research and Clinical Practice, 2015, 110, 234-240.	1.1	8
263	Improving Diabetes Care in the Latino Population: The Emory Latino Diabetes Education Program. American Journal of Health Education, 2016, 47, 1-7.	0.3	8
264	A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens. PharmacoEconomics - Open, 2017, 1, 109-115.	0.9	8
265	Hypoglycaemia and its management in primary care setting. Diabetes/Metabolism Research and Reviews, 2020, 36, e3332.	1.7	8
266	Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2673-e2679.	1.8	8
267	Latent tuberculosis infection among patients with and without type-2 diabetes mellitus: results from a hospital case-control study in Atlanta. BMC Research Notes, 2021, 14, 252.	0.6	8
268	Inpatient management of diabetes: An increasing challenge to the hospitalist physician. Journal of Hospital Medicine, 2007, 2, 33-35.	0.7	7
269	Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 637-641.	1.2	7
270	Changes in Inflammatory and Bone Turnover Markers After Periodontal Disease Treatment in Patients With Diabetes. American Journal of the Medical Sciences, 2016, 351, 589-594.	0.4	7

#	Article	IF	CITATIONS
271	Dental loss among ambulatory patients with diabetes. Journal of Clinical and Translational Endocrinology, 2016, 4, 28-31.	1.0	7
272	A Self-assessment Tool for Screening Young Adults at Risk of Type 2 Diabetes Using Strong Heart Family Study Data. The Diabetes Educator, 2016, 42, 607-617.	2.6	7
273	2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes. Diabetes Spectrum, 2018, 31, 254-260.	0.4	7
274	Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes. Primary Care Diabetes, 2020, 14, 193-212.	0.9	7
275	Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. Diabetes Technology and Therapeutics, 2021, 23, 715-725.	2.4	7
276	Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study. Journal of Clinical Medicine, 2022, 11, 2813.	1.0	7
277	Time-dependent glycemic variability and mortality in critically ill patients with diabetes*. Critical Care Medicine, 2011, 39, 211-213.	0.4	6
278	Comparison of Basal Insulin Regimens on Glycemic Variability in Noncritically Ill Patients with Type 2 Diabetes. Endocrine Practice, 2015, 21, 1333-1343.	1.1	6
279	Management of diabetic ketoacidosis and hyperglycemic hyperosmolar state in adults. Expert Review of Endocrinology and Metabolism, 2016, 11, 177-185.	1.2	6
280	Association of glucose variability at the last day of hospitalization with 30-day readmission in adults with diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e000990.	1.2	6
281	Selecting Insulin Regimens for the Management of Non-ICU Patients With Type 2 Diabetes. Journal of the Endocrine Society, 2021, 5, bvab134.	0.1	6
282	Annals for Hospitalists Inpatient Notes - How We Treat Hyperglycemia in the Hospital. Annals of Internal Medicine, 2021, 174, HO2-HO4.	2.0	6
283	A Temporal Abstraction-based Extract, Transform and Load Process for Creating Registry Databases for Research. AMIA Summits on Translational Science Proceedings, 2011, 2011, 46-50.	0.4	6
284	Characteristics associated with early- vs. later-onset adult diabetes: The CARDIA study. Diabetes Research and Clinical Practice, 2021, 182, 109144.	1.1	6
285	Intermediary Variables and Algorithm Parameters for an Electronic Algorithm for Intravenous Insulin Infusion. Journal of Diabetes Science and Technology, 2009, 3, 835-856.	1.3	5
286	Diabetes prevention: Can insulin secretagogues do the job?. Primary Care Diabetes, 2011, 5, 73-80.	0.9	5
287	Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus. Evidence-Based Medicine, 2016, 21, 104-105.	0.6	5
288	Aace/ace Position Statement on the use of follow-on Biologics and Biosimilars for Endocrine Diseases. Endocrine Practice, 2017, 23, 1345-1349.	1.1	5

#	Article	IF	Citations
289	Dietary Behaviors and Glucose Metabolism in Young Adults at Risk for Type 2 Diabetes. The Diabetes Educator, 2018, 44, 158-167.	2.6	5
290	Recommendations for management of diabetes and its complications during Hajj (Muslim pilgrimage). BMJ Open Diabetes Research and Care, 2018, 6, e000574.	1.2	5
291	Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide. Diabetes, Obesity and Metabolism, 2019, 21, 1365-1372.	2.2	5
292	Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery. BMJ Open Diabetes Research and Care, 2019, 7, e000703.	1,2	5
293	Challenges and Strategies for Inpatient Diabetes Management in Older Adults. Diabetes Spectrum, 2020, 33, 227-235.	0.4	5
294	Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 480-488.	2.2	5
295	Improving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitus. Patient Preference and Adherence, 2015, 9, 619.	0.8	4
296	The Importance of Social Support on Glycemic Control in Low-income Latinos With Type 2 Diabetes. American Journal of Health Education, 2016, 47, 279-286.	0.3	4
297	An Atypical Presentation of Diabetic Myonecrosis. AACE Clinical Case Reports, 2019, 5, e77-e81.	0.4	4
298	When basal insulin is not enough: response to M Davidson. Diabetes, Obesity and Metabolism, 2020, 22, 711-712.	2.2	4
299	Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations. Ethnicity and Disease, 2006, 16, 51-7.	1.0	4
300	Efficacy and Safety of Intensive Versus Nonintensive Supplemental Insulin With a Basal-Bolus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Clinical Study. Diabetes Care, 2022, 45, 2217-2223.	4.3	4
301	Obtaining Positive Outcomes with Insulin Therapy in Hospitalized Patients. Insulin, 2007, 2, S47-S56.	0.2	3
302	Multiplicative Surrogate Standard Deviation: A Group Metric for the Glycemic Variability of Individual Hospitalized Patients. Journal of Diabetes Science and Technology, 2013, 7, 1319-1327.	1.3	3
303	A Quadruply-Asymmetric Sigmoid to Describe the Insulin-Glucose Relationship during Intravenous Insulin Infusion. Journal of Healthcare Engineering, 2014, 5, 23-54.	1.1	3
304	Update on Inpatient Diabetes Management: Call for Action. Diabetes Technology and Therapeutics, 2015, 17, 225-228.	2.4	3
305	Abbas E. Kitabchi, PhD, MD: An Exemplary Mentor and Clinical Researcher. Diabetes Care, 2016, 39, 333-336.	4.3	3
306	Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589. Diabetes Care, 2019, 42, e66-e67.	4.3	3

#	Article	IF	CITATIONS
307	Population insulin sensitivity from sparsely sampled oral glucose tolerance tests. Metabolism: Clinical and Experimental, 2020, 110, 154298.	1.5	3
308	Diabetes management in urban African Americans: review of a public hospital experience. Ethnicity and Disease, 2008, 18, 336-41.	1.0	3
309	Inpatient insulin therapy. Insulin, 2008, 3, 152-166.	0.2	2
310	Efficacy and Safety of Liraglutide vs. Placebo as Add-On to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL). Canadian Journal of Diabetes, 2014, 38, S9-S10.	0.4	2
311	Insulin Glargine/Lixisenatide Fixed Ratio Combination Improves Glycemic Variability in Type 2 Diabetes. Canadian Journal of Diabetes, 2016, 40, S45-S46.	0.4	2
312	Are We Ready to Move Beyond Capillary Glucose Testing and Insulin Injections?. American Journal of the Medical Sciences, 2019, 358, 315-316.	0.4	2
313	The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control. Journal of Diabetes Science and Technology, 2021, 15, 371-376.	1.3	2
314	Implementation of App-Based Diabetes Medication Management: Outpatient and Perioperative Clinical Decision Support. Current Diabetes Reports, 2021, 21, 50.	1.7	2
315	InsulinAPP application protocol for the inpatient management of type 2 diabetes on a hospitalist-managed ward: a retrospective study. Archives of Endocrinology and Metabolism, 2022, , .	0.3	2
316	MANAGEMENT OF TYPE 2 DIABETES. Obstetrics and Gynecology Clinics of North America, 2001, 28, 401-420.	0.7	1
317	Intensive Insulin Therapy in Hospitalized Patients. Annals of Internal Medicine, 2011, 154, 846.	2.0	1
318	Lixisenatide Reduces Glycemic Variability When Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2014, 38, S40.	0.4	1
319	Hyperglycemic Crises., 2016,, 805-815.e3.		1
320	In Reply. Anesthesiology, 2017, 127, 900-901.	1.3	1
321	Management of Inpatient Hyperglycemia and Diabetes in Older Adults. Clinics in Geriatric Medicine, 2020, 36, 491-511.	1.0	1
322	Long-term changes in carbohydrate tolerance, insulin secretion and action in African-American patients with obesity and history of hyperglycemic crises. BMJ Open Diabetes Research and Care, 2020, 8, e001062.	1.2	1
323	Management of glycemic crises in adult patients with diabetes mellitus: Evidence-based Clinical Practice Guideline, Lima - Peru Revista De La Facultad De Medicina Humana, 2021, 21, 50-64.	0.1	1
324	908-P: Accuracy Comparison of the Freestyle Libre Pro Continuous Glucose Monitoring (CGM) and Point-of-Care (POC) Testing in Noncritically III Hospitalized Patients with Type 2 Diabetes Treated with Basal-Bolus Insulin Regimen. Diabetes, 2019, 68, .	0.3	1

#	Article	IF	CITATIONS
325	Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Endocrinology, 2020, , 595-614.	0.1	1
326	Heart rate variability and HbA1c predict plasma interleukin-6 response to psychosocial stress challenge in trauma-exposed women with type 2 diabetes. Brain, Behavior, & Immunity - Health, 2021, 19, 100400.	1.3	1
327	Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1411-1422.	2.2	1
328	1-h Glucose During Oral Glucose Tolerance Test Predicts Hyperglycemia Relapse-Free Survival in Obese Black Patients With Hyperglycemic Crises. Frontiers in Endocrinology, 2022, 13, .	1.5	1
329	Improving Insulin Sensitivity: A Review of New Therapies. Clinical Cornerstone, 2008, 9, S28-S38.	1.0	0
330	La diabetes de tipo 2 y los secretagogos de insulina. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 38A-38A.	1.8	0
331	Diabetes and Atherosclerotic Cardiovascular Disease: Novel Insights and Therapeutic Strategies. Endocrinology and Metabolism Clinics of North America, 2018, 47, xv-xvi.	1.2	0
332	Pearls for Your Practice: A Clinician's Guide to Recently Published Guidelines and Position Statements. Diabetes Spectrum, 2018, 31, 215-216.	0.4	0
333	Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Endocrinology, 2018, , 1-21.	0.1	0
334	Rebuttals to "The Debate on Insulin vs. Non-insulin Use in the Hospital Settingâ€"Continued Use of Insulin or Time to Revise the Guidelines?― Current Diabetes Reports, 2019, 19, 66.	1.7	0
335	Efficacy and Safety of Iglarlixi in Hispanics and Non-Hispanic Whites with Type 2 Diabetes. Endocrine Practice, 2019, 25, 1091-1100.	1.1	0
336	459. Gaps in Diabetic Foot Care in an Inner-City Hospital. Open Forum Infectious Diseases, 2019, 6, S225-S226.	0.4	0
337	Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589. Diabetes Care, 2019, 42, e15-e15.	4.3	0
338	Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia. Journal of Diabetes Science and Technology, 2021, 15, 1181-1187.	1.3	0
339	La diabetes y el ejercicio. Journal of Clinical Endocrinology and Metabolism, 2008, 93, E1-E1.	1.8	0
340	2012 Reviewers for Endocrine Practice. Endocrine Practice, 2012, 18, 1040-1041.	1.1	0
341	Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Endocrinology, 2018, , 595-615.	0.1	0
342	Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Endocrinology, 2019, , 1-21.	0.1	0

#	Article	IF	CITATIONS
343	Creating diabetes guidelines for the individual not just the illness. Lancet Diabetes and Endocrinology,the, 2022, 10, 238-240.	<b>5.</b> 5	O
344	Trimetazidine Blocks Lipid Oxidation—Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?. Journal of Diabetes Science and Technology, 0, , 193229682211001.	1.3	0